Ipsen to acquire Albireo accelerating growth in rare disease with
https://www.ipsen.com/press-releases/ipsen-to-acquire-albireo-accelerating-growth-in-rare-disease-with-treatments-for-several-pediatric-liver-diseases/
WebJan 9, 2023 · PARIS, FRANCE & BOSTON, U.S., 09 January 2023 – Ipsen (Euronext: IPN: ADR: IPSEY) and Albireo (Nasdaq: ALBO) today announced that they have entered into a definitive merger agreement under which Ipsen will acquire Albireo, a leading innovator in bile-acid modulators to treat pediatric and adult cholestatic liver diseases.
DA: 94 PA: 48 MOZ Rank: 3